Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac + levomenthol (MFC51123) is a topical combination gel developed by GSK Consumer Healthcare for the treatment of pain and inflammation associated with acute musculoskeletal injuries, such as ankle sprains. It contains 1% diclofenac, a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), and 3% levomenthol, a cooling agent that acts as an agonist on TRPM8 cold receptors. This combination is designed to provide rapid pain relief through the immediate cooling sensation of menthol and the sustained anti-inflammatory action of diclofenac. It has been evaluated in Phase 3 clinical trials comparing its efficacy against placebo and monotherapy components.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + levomenthol.